Hosted on MSN3mon
FDA Says Shortage of Eli Lilly’s Zepbound Is Over, but Gives Compounders a Grace Periodjust months after the launch of Mounjaro and before the launch of Zepbound. Supply issues have hampered the drug’s uptake, and Lilly has invested heavily in increasing its manufacturing output.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback